Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
Terminated · Phase 1 · NCT05956509
Conditions: Upper Limb Spasticity
At a glance
- Research payments reported, 2025
- $750
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-950 (biological), BOTOX (biological), Placebo for ABBV-950 (drug)
- Dates
- Started 2024-01-12; completion 2024-06-02
- Results posted
- Not yet
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. Common causes of spasticity include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke. This study will assess how safe and effective ABBV-950 is in treating upper limb spasticity in adult post-stroke participants. Adverse events and change in symptoms will be assessed. ABBV-950 in an investigational drug being developed for treating spasticity. This study is conducted in 2 parts. In Part 1, participants are assigned to receive different doses of ABBV-9…
From ClinicalTrials.gov, last updated 2024-07-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $750 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Texas $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.